PDF herunterladen
Semin Liver Dis 2004; 24: 69-77
DOI: 10.1055/s-2004-832931
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hepatitis C Infection Associated with Renal Disease and Chronic Renal Failure

Fred F. Poordad1 , Fabrizio Fabrizi1 , 2 , Paul Martin1
  • 1The Center for Liver and Kidney Diseases and Transplantation, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California
  • 2The Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
02. September 2004 (online)

    Lizenzen und Reprints

Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.

KEYWORDS

HCV - chronic renal failure - renal disease - renal transplantation - interferon

REFERENCES

  • 1 Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives.  Int J Artif Organs. 2000;  23 805-816
    PubMedGoogle Scholar
  • 2 Fabrizi F, Martin P, Dixit V et al.. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay.  Am J Kidney Dis. 1998;  31 647-654
    PubMedGoogle Scholar
  • 3 Lombardi M, Cerrai T, Geatti S et al.. Results of a national epidemiological investigation on HCV infection among dialysis patients.  J Nephrol. 1999;  12 322-327
    PubMedGoogle Scholar
  • 4 Maisonneuve P, Agodoa L, Gellert R et al.. Cancer in patients on dialysis for end-stage renal disease. An international collaborative study.  Lancet. 1999;  354 93-99
    CrossrefPubMedGoogle Scholar
  • 5 Espinosa M, Martin-Malo A, Alvarez de Lara M, Alijama P. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients.  Nephrol Dial Transplant. 2001;  16 1669-1674
    PubMedGoogle Scholar
  • 6 Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy.  J Am Soc Nephrol. 2000;  11 1896-1902
    PubMedGoogle Scholar
  • 7 Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation.  Am J Kidney Dis. 2001;  38 919-934
    PubMedGoogle Scholar
  • 8 Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaries Cliniques St-Luc (UCL) Collaborative Group.  Kidney Int. 1998;  53 1022-1025
    CrossrefPubMedGoogle Scholar
  • 9 Schneeberger P M, Keur I, van Loon A M et al.. The prevalence and incidence of hepatitis C virus infection among dialysis patients in the Netherlands: a nationwide prospective study.  J Infect Dis. 2000;  182 1291-1299
    CrossrefPubMedGoogle Scholar
  • 10 Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study.  J Med Virol. 2000;  61 44-51
    CrossrefPubMedGoogle Scholar
  • 11 Qian K P, Natov S N, Pereira B J, Lau J Y. Hepatitis C virus mixed genotype infection in patients on haemodialysis.  J Viral Hepat. 2000;  7 153-160
    CrossrefPubMedGoogle Scholar
  • 12 Todorov V, Boneva R, Ilieva P et al.. High prevalence of hepatitis C virus infection in one dialysis center in Bulgaria.  Nephron. 1998;  79 222-223
    CrossrefPubMedGoogle Scholar
  • 13 Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study.  Int J Artif Organs. 2000;  23 181-188
    PubMedGoogle Scholar
  • 14 Covic A, Iancu L, Apetrei C et al.. Hepatitis virus infection in haemodialysis patients from Moldavia.  Nephrol Dial Transplant. 1999;  14 40-45
    PubMedGoogle Scholar
  • 15 Valtuille R, Moretto H, Lef L et al.. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow up.  Clin Nephrol. 2002;  57 371-375
    PubMedGoogle Scholar
  • 16 Marcelli D, Stanhard D, Conte F et al.. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.  Kidney Int. 1996;  50 1013-1018
    PubMedGoogle Scholar
  • 17 Stehman-Breen C O, Emerson S, Gretch D, Johnson R J. Risk of death among chronic dialysis patients infected with hepatitis C virus.  Am J Kidney Dis. 1998;  32 629-634
    PubMedGoogle Scholar
  • 18 Fabrizi F, Lunghi G, Guarnori I et al.. Virological characteristics of hepatitis C virus infection in chronic hemodialysis patients: a cross-sectional survey.  Clin Nephrol. 1995;  44 49-55
    PubMedGoogle Scholar
  • 19 Picciotto A, Varagona G, Gurreri G et al.. Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in hemodialysis patients.  Nephrol Dial Transplant. 1993;  8 1115-1117
    PubMedGoogle Scholar
  • 20 Pol S, Romeo R, Zins B et al.. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications.  Kidney Int. 1993;  44 1097-1100
    PubMedGoogle Scholar
  • 21 Chan T M, Lok A SF, Cheng I KP, Chan R T. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays.  Hepatology. 1993;  17 5-8
    CrossrefPubMedGoogle Scholar
  • 22 Bukh J, Wantzin P, Krogsgaard K et al.. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number with HCV infection.  J Infect Dis. 1993;  168 1343-1348
    CrossrefPubMedGoogle Scholar
  • 23 Fabrizi F, Martin P, Dixit V et al.. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey.  Nephron. 1998;  80 428-433
    CrossrefPubMedGoogle Scholar
  • 24 Martin P, Carter D, Fabrizi F et al.. Histopathological features of hepatitis C in renal transplant candidates.  Transplantation. 2000;  69 1479-1484
    CrossrefPubMedGoogle Scholar
  • 25 Sterling R K, Sanyal A J, Luketic V A et al.. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation.  Am J Gastroenterol. 1999;  94 3576-3582
    CrossrefPubMedGoogle Scholar
  • 26 Saab S, Martin P, Brezina M et al.. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis.  Am J Kidney Dis. 2001;  37 308-315
    PubMedGoogle Scholar
  • 27 Saab S, Brezina M, Gitnick G et al.. Hepatitis C screening strategies in hemodialysis patients.  Am J Kidney Dis. 2001;  38 91-97
    PubMedGoogle Scholar
  • 28 Fabrizi F, Martin P, Dixit V et al.. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus.  Am J Kidney Dis. 2000;  35 122-129
    PubMedGoogle Scholar
  • 29 Fabrizi F, Martin P, Dixit V et al.. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients.  Am J Nephrol. 1999;  19 383-388
    CrossrefPubMedGoogle Scholar
  • 30 Koenig P, Vogel W, Umlauft F et al.. Interferon treatment for chronic hepatitis C virus infection in uremic patients.  Kidney Int. 1994;  45 1507-1509
    PubMedGoogle Scholar
  • 31 Pol S, Thiers V, Carnot F et al.. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients.  Kidney Int. 1995;  47 1412-1418
    PubMedGoogle Scholar
  • 32 Raptopoulou-Gigi M, Spaia S, Garifallos A et al.. Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients.  Nephrol Dial Transplant. 1995;  10 1834-1837
    PubMedGoogle Scholar
  • 33 Fernandez J L, Rendo P, Del Pino N. Nephrologists' group for the study of HCV infection . Viola L. A double-blind controlled trial of recombinant interferon-alpha2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels.  J Viral Hep. 1997;  4 113-119
    PubMedGoogle Scholar
  • 34 Izopet J, Rostaing L, Moussion F et al.. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-therapy.  J Infect Dis. 1997;  176 1614-1617
    PubMedGoogle Scholar
  • 35 Chan T M, Wu P C, Lau J YN, Lok A SF, Lai C L, Cheng K P. Interferon treatment for hepatitis C virus infection in patients on haemodialysis.  Nephrol Dial Transplant. 1997;  12 1414-1419
    PubMedGoogle Scholar
  • 36 Uchihara M, Izumi N, Sakai Y et al.. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon.  Nephron. 1998;  80 51-56
    CrossrefPubMedGoogle Scholar
  • 37 Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti P B. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C.  Curr Med Res Opin. 1998;  14 141-144
    PubMedGoogle Scholar
  • 38 Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C.  Am J Nephrol. 2001;  21 435-440
    CrossrefPubMedGoogle Scholar
  • 39 Campistol J M, Esforzado N, Martinez J et al.. Efficacy and tolerance of interferon-a2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.  Nephrol Dial Transplant. 1999;  14 2704-2709
    PubMedGoogle Scholar
  • 40 Espinosa M, Rodriguez M, Martin-Malo A et al.. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.  Clin Nephrol. 2001;  55 220-226
    PubMedGoogle Scholar
  • 41 Casanovas-Taltavull T, Baliellas C, Benasco C et al.. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidneys transplant candidates on hemodialysis: results after transplantation.  Am J Gastroenterol. 2001;  96 1170-1177
    PubMedGoogle Scholar
  • 42 Hanrotel C, Toupance O, Lavaud S et al.. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.  Nephron. 2001;  88 120-126
    CrossrefPubMedGoogle Scholar
  • 43 Degos F, Pol S, Chaix M L et al.. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study.  Nephrol Dial Transplant. 2001;  16 1017-1023
    CrossrefPubMedGoogle Scholar
  • 44 Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.  Aliment Pharmacol Ther. 2003;  18 1071-1081
    CrossrefPubMedGoogle Scholar
  • 45 Russo M W, Goldsweig C D, Jacobson I M, Brown R S. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.  Am J Gastroenterol. 2003;  98 1610-1615
    CrossrefPubMedGoogle Scholar
  • 46 Izzedine H, Lebon P, Launay-Vacher V et al.. Tolerance and pharmacokinetics of high doses of interpheron-alpha-2a in a hemodialysis patient.  Nephron. 2001;  87 91-92
    CrossrefPubMedGoogle Scholar
  • 47 Hirsch M S, Tolkoff-Rubin N E, Kelly A P, Rubin R H. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis.  J Infect Dis. 1983;  148 335
    PubMedGoogle Scholar
  • 48 Rostaing L, Chatelut E, Payen J L et al.. Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus undergoing chronic hemodialysis or with normal renal function: clinical implications.  J Am Soc Nephrol. 1998;  9 2344-2348
    PubMedGoogle Scholar
  • 49 Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.  Nephrol Dial Transplant. 2001;  16 1729
    PubMedGoogle Scholar
  • 50 Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study.  J Viral Hepat. 2001;  8 287-292
    CrossrefPubMedGoogle Scholar
  • 51 Tan A C, Brouwer J T, Glue P et al.. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.  Nephrol Dial Transplant. 2001;  16 193-195
    PubMedGoogle Scholar
  • 52 Reddy K R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs.  Ann Pharmacother. 2000;  34 915-923
    CrossrefPubMedGoogle Scholar
  • 53 Martin P, Mitra S, Farrington K et al.. Pegylated (40KDA) interferon alfa-2a (Pegasys) is unaffected by renal impairment.  Hepatology. 2000;  32 370A
    PubMedGoogle Scholar
  • 54 Lamb M W, Marks I M, Wynohradnyk L et al.. 40 kDa peginterferon alfa-2a (Pegasys) can be administered safely in patients with end-stage renal disease.  Hepatology. 2001;  34 326A
    PubMedGoogle Scholar
  • 55 Bunnapradist S, Fabrizi F, Vierling J et al.. Hepatitis C therapy with long term remission after renal transplantation.  Int J Artif Organs. 2002;  25 1189-1193
    PubMedGoogle Scholar
  • 56 Pereira B J, Levey A S. Hepatitis C virus infection in dialysis and renal transplantation.  Kidney Int. 1997;  51 981-999
    CrossrefPubMedGoogle Scholar
  • 57 Zucker K, Cirocco R, Roth D et al.. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation.  Transplantation. 1994;  57 832-840
    PubMedGoogle Scholar
  • 58 Roth D, Fernandez J A, Babishkin S et al.. Transmission of hepatitis C virus solid organ transplantation: incidence and clinical significance.  Transplant Proc. 1993;  25 1476-1477
    PubMedGoogle Scholar
  • 59 Tesi R J, Waller K, Morgan M L, Ferguson R M. Transmission of hepatitis C by kidney transplantation-the risks.  Transplantation. 1994;  57 826-831
    PubMedGoogle Scholar
  • 60 Vincenti F, Lake J, Wright T et al.. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients.  Transplantation. 1993;  55 674-675
    PubMedGoogle Scholar
  • 61 Fabrizi F, Marai P, Raffaele L et al.. Hepatitis C virus infection in kidney graft recipients: a study with second-generation assays.  Nephrol Dial Transplant. 1992;  7 1164-1165
    PubMedGoogle Scholar
  • 62 Rostaing L, Izopet J, Cisterne J M et al.. Prevalence of antibodies to hepatitis C virus and correlation with liver disease in renal transplant patients.  Am J Nephrol. 1997;  17 46-52
    PubMedGoogle Scholar
  • 63 Lau J YN, Davis G L, Brunson M E et al.. Hepatitis C virus infection in kidney transplant recipients.  Hepatology. 1993;  18 1027-1031
    CrossrefPubMedGoogle Scholar
  • 64 Roth D, Zucker K, Cirocco R et al.. The impact of hepatitis C virus infection on renal allograft recipients.  Kidney Int. 1994;  45 238-244
    PubMedGoogle Scholar
  • 65 Chan T M, Lok A SF, Chang I KP. Hepatitis C in renal transplant recipients.  Transplantation. 1991;  52 810-813
    PubMedGoogle Scholar
  • 66 Mahmoud I, Sobh M A, Am G M et al.. Prospective study of hepatitis C viremia in renal allograft recipients.  Am J Nephrol. 1999;  19 576-585
    CrossrefPubMedGoogle Scholar
  • 67 Pereira B J, Natov S N, Bouthot B A et al.. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group.  Kidney Int. 1998;  53 1374-1381
    CrossrefPubMedGoogle Scholar
  • 68 Knoll G A, Tankersley M R, Lee J Y et al.. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients.  Am J Kidney Dis. 1997;  29 608-614
    PubMedGoogle Scholar
  • 69 Kliem V, van den Hoff U, Brunkhorst R et al.. The long-term course of hepatitis C after kidney transplantation.  Transplantation. 1996;  62 1417-1421
    PubMedGoogle Scholar
  • 70 Gentil M A, Rocha J L, Rodriguez-Algarra G et al.. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus.  Nephrol Dial Transplant. 1999;  14 2455-2460
    PubMedGoogle Scholar
  • 71 Mathurin P, Mouquet C, Poynard T et al.. Impact of hepatitis B and C virus on kidney transplantation outcome.  Hepatology. 1999;  29 257-263
    CrossrefPubMedGoogle Scholar
  • 72 Batty D S, Swanson S J, Kirk A D et al.. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival.  Am J Transplant. 2001;  1 179-184
    PubMedGoogle Scholar
  • 73 Rostaing L, Izopet J, Baron E et al.. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.  Transplantation. 1995;  59 1426-1431
    CrossrefPubMedGoogle Scholar
  • 74 Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C.  Nephrol Dial Transplant. 1995;  10 2104-2106
    PubMedGoogle Scholar
  • 75 Thervet E, Pol S, Legendre C et al.. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study.  Transplantation. 1994;  58 625-628
    PubMedGoogle Scholar
  • 76 Garnier J L, Chevallier P, Dubernard J M et al.. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients.  Transplant Proc. 1997;  29 783
    CrossrefPubMedGoogle Scholar
  • 77 Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights.  Nephrol Dial Transplant. 2000;  15 74-76
    PubMedGoogle Scholar
  • 78 Misiani R, Bellavita P, Fenili D et al.. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Engl J Med. 1994;  330 751-756
    CrossrefPubMedGoogle Scholar
  • 79 Ferri C, Marzo E, Longombardo G. Interpheron alpha in mixed cryoglobulinemia patients: a randomized, cross-over controlled trial.  Blood. 1993;  81 1132-1136
    PubMedGoogle Scholar
  • 80 Dammacco F, Sansonno D, Han J H et al.. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type-II mixed cryoglobulinemia: a long-term, randomized, controlled study.  Blood. 1994;  84 3336-3343
    PubMedGoogle Scholar
  • 81 Johnson R J, Gretch D R, Couser W G et al.. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.  Kidney Int. 1994;  46 1700-1704
    PubMedGoogle Scholar
  • 82 Misiani R, Bellavita P, Baio P et al.. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.  Nephrol Dial Transplant. 1999;  14 1558-1560
    PubMedGoogle Scholar
  • 83 Quigg R J, Brathwaite M, Gardner D F et al.. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection.  Am J Kidney Dis. 1995;  25 798-800
    PubMedGoogle Scholar
  • 84 Gilli P, Stabellini N, Storari A et al.. Effect of human leukocyte alpha interferon on cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection.  Nephrol Dial Transplant. 1996;  11 526-538
    PubMedGoogle Scholar
  • 85 Sarac E, Bastacky S, Johnson J P. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection.  Am J Kidney Dis. 1997;  30 113-115
    PubMedGoogle Scholar
  • 86 Yamabe H, Johnson R J, Gretch D R et al.. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha.  Am J Kidney Dis. 1995;  25 67-69
    PubMedGoogle Scholar
  • 87 Morosetti M, Sciarra G, Meloni C et al.. Membranoproliferative glomerulonephritis and hepatitis C: Effects of interferon-alpha therapy on clinical outcome and histologic pattern.  Nephrol Dial Transplant. 1996;  11 532-534
    PubMedGoogle Scholar
  • 88 Garini G, Allegri L, Carnevali L et al.. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C-virus associated cryoglobulinemic membranoproliferative glomerulonephritis.  Am J Kidney Dis. 2001;  38 E35
    PubMedGoogle Scholar
  • 89 D’Amico G. Nephrology forum: renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.  Kidney Int. 1998;  54 650-671
    CrossrefPubMedGoogle Scholar
  • 90 Baid S, Cosimi A B, Tolkoff-Rubin N et al.. Renal disease associated with hepatitis C infection after kidney and liver transplantation.  Transplantation. 2000;  70 255-261
    PubMedGoogle Scholar
  • 91 Davis C L, Gretch D R, Perkins J D et al.. Hepatitis C-associated glomerular disease in liver transplant recipients.  Liver Transpl Surg. 1995;  3 166-175
    PubMedGoogle Scholar
  • 92 Kendrick E A, McVicar J P, Kowdley K V et al.. Renal disease in hepatitis C-positive liver transplant recipients.  Transplantation. 1997;  63 1287-1293
    PubMedGoogle Scholar
  • 93 Pham H P, Feray C, Samuel D et al.. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.  Kidney Int. 1998;  54 1311-1319
    CrossrefPubMedGoogle Scholar

Paul MartinM.D. 

Center for Liver and Kidney Diseases and Transplantation, Cedars-Sinai Medical Center

8635 W 3rd Street, Suite 590W

Los Angeles, CA 90048

eMail: martinpx@cshs.org